Oncology drugs

Another unanswered question is the evaluation of the effect on cardiac repolarization of oncologic drugs, for which the thorough QT/QTc study in volunteers cannot be performed [166], In these cases, not only central tendency (i.e. mean QTc increase) and proportion of outliers but also other findings such as syncope, ventricular tachyarrhythmias and other cardiac effects should be more closely defined. 

Morganroth, J. (2007) Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Research Foundation Workshop, Springer-Verlag, Berlin, 171-184. 

Portney NG, Ozkan M (2006) Nano-oncology drug delivery, imaging, and sensing. Analytical and Bioanalytical Chemistry 384 620-630. 

This classification is less relevant to the fine-chemical industry. It should only be noted that the ratio between small and big molecules varies according to the individual class. For instance, small molecules prevail in antihypertensives large ones, in oncology drugs. 

GERMLINE PHARMACOGENETICS IN ONCOLOGY DRUG DEVELOPMENT LEARNING FROM LAPATINIB... 

Dracopoli NC. Development of oncology drug response markers using transcription profiling. Curr Mol Med2005 5 03-U0. 

Slater and Savelski note similar trends in solvent use and waste reduction for a new oncology drug under development at BMS [1]. They indicate that the best opportunities to make a process greener occur in the early stages of drug develop-... 

In oncology, drug dosage individualization for conventional cytotoxic anticancer therapy is performed according to mg/m2 or mg/kg. However, even after dose adjustment, the pharmacokinetic variability observed for many cytotoxic... 

---